Patents by Inventor Graham Alexander ROSS

Graham Alexander ROSS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adjuvant treatment of HER2-positive breast cancer
    Patent number: 11638756
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: May 2, 2023
    Assignees: Genentech, Inc., Hoffman-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
    Publication number: 20230000977
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Application
    Filed: August 22, 2022
    Publication date: January 5, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. BENYUNES, Graham Alexander ROSS
  • ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
    Publication number: 20210330789
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Application
    Filed: July 9, 2021
    Publication date: October 28, 2021
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. BENYUNES, Graham Alexander ROSS
  • Adjuvant treatment of HER2-positive breast cancer
    Patent number: 11077189
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 3, 2021
    Assignees: Genentech Inc., Hoffmann La-Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
    Publication number: 20180250397
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Application
    Filed: February 28, 2018
    Publication date: September 6, 2018
    Applicants: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Mark C. BENYUNES, Graham Alexander ROSS